Luke Selth

Research Interests

Cancer Biology and Clinical Oncology Cancer Cell Biology Cancer Therapy

APrf Luke Selth

School of Medicine

College of Health

Eligible to supervise Masters and PhD as Principal Supervisor - email supervisor to discuss availability.

Associate Professor Luke Selth
 
Luke Selth is an Associate Professor at Flinders University and has an Adjunct Associate Professor position associated with the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL), Adelaide Medical School. He is a Cancer Council SA Beat Cancer Principal Cancer Research Fellow in the Flinders Health and Medical Research Institute (FHMRI), where he leads the Prostate Cancer Research Group. He is also member of the Freemasons Centre for Male Health and Wellbeing (FCMHW) and sits on the Scientific Advisory Committee for the South Australian Genomics Centre.
 
Research in the Selth lab focuses on two aspects of prostate cancer development and progression. The first is aimed at investigating the mechanisms underlying continued androgen signalling in lethal forms of prostate cancer. The second involves research into the role of microRNAs in prostate carcinogenesis and metastasis and their use as potential biomarkers of disease. These research programs utilise contemporary "omic" techniques to better understand prostate cancer at the molecular level.
 
Selth is a past Young Investigator of Prostate Cancer Foundation of Australia and the Prostate Cancer Foundation (USA). His research is currently funded by competitive grants from various bodies, including Cancer Council SA, Cancer Australia, Movember and The Hospital Research Foundation.
 
A range of PhD and Honours projects are available in Selth's lab for motivated students - please contact him directly at luke.selth@flinders.edu.au if you are interested.

 

 

Date Position Institution name
2019 - ongoing Associate Professor Flinders University
2019 - ongoing Adjunct Associate Professor University of Adelaide
2015 - 2019 Senior Research Fellow University of Adelaide
2009 - 2014 Research Fellow University of Adelaide
2005 - 2009 Post-doctoral Fellow Cancer Research UK London Research Institute

Date Type Title Institution Name Country Amount
2016 Fellowship Endeavour Research Fellowship - - -
2015 Research Award Australian Society for Medical Research Leading Light Award (finalist) - - -
2013 Award South Australian Young Tall Poppy Science Award - - -
2012 Award Prostate Cancer Foundation Young Investigator Award - - -
2011 Award Millennium Sciences Award (Lorne Genome Conference) - - -
2011 Award Prostate Cancer Foundation of Australia Young Investigator Award - - -
2010 Award International Conference Award University of Adelaide Faculty of Health Sciences - -
2005 Fellowship European Molecular Biology Organisation (EMBO) Long-Term Fellowship - - -

Date Institution name Country Title
2005 University of Adelaide Australia PhD
2000 Flinders University Australia B. Biotechnology (Honours)

Year Citation
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy-Naïve Localized Prostate Cancer.. Cancer Research, 86(8), 1836-1853.
DOI Scopus1 WoS1
2026 Fang, D. M., Shrestha, R. K., German, B., Rahman, R., Townley, S. L., Xie, J., . . . Selth, L. A. (2026). USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer.. Cell Death Dis, 17(1), 13 pages.
DOI Scopus1 WoS1
2026 Safaroghli-Azar, A., Croft, T., Mekonnen, L. B., Lenjisa, J., Dickel, M., Shrestha, R. K., . . . Wang, S. (2026). CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer. Journal of Experimental and Clinical Cancer Research, 45(1), 188-1-188-23.
DOI
2026 O’Callaghan, M. E., Selth, L., & Wittert, G. (2026). Re: Testosterone Treatment in Prostate Cancer Survivors with Hypogonadism: A Randomized Clinical Trial. European Urology, S0302-2838(26)02262-1.
DOI
2026 Le Magnen, C., Brennen, W. N., Aytes, Á., Bock, N., Bristow, R. G., Choo, N., . . . Lawrence, M. G. (2026). Patient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis. Cancer Letters, 659, 17 pages.
DOI
2025 John, A., Milton, T., Gupta, A., Nguyen, M. T., Stretton, B., Hewitt, J., . . . Callaghan, M. O. (2025). Impact of positive surgical margin location after radical prostatectomy: a network meta-analysis. World Journal of Urology, 43(1), 11 pages.
DOI Scopus12 WoS9 Europe PMC4
2025 Rahman, R., & Selth, L. A. (2025). Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer. Translational Oncology, 55, 15 pages.
DOI Scopus2 WoS2 Europe PMC1
2025 Lawrence, M. G., Keerthikumar, S., Townley, S. L., Clark, A. K., Cuffe, G. B., Laven-Law, G., . . . Selth, L. A. (2025). Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.. European urology focus, 11(5), S2405-4569(25)00073-2.
DOI Scopus5 WoS5 Europe PMC4
2025 Toubia, J., Kusay, Y., Maqsood, M., Warnock, N. I., Lawrence, D. M., Bracken, C. P., . . . Schreiber, A. W. (2025). TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets. NAR Genomics and Bioinformatics, 7(2), lqaf041-1-lqaf041-13.
DOI Scopus2 WoS2 Europe PMC1
2025 Xie, J., Shen, K., Liang, W., Kuang, Z., Shrestha, R. K., Hanson, A. R., . . . Selth, L. A. (2025). Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival. Proceedings of the National Academy of Sciences of the United States of America, 122(42), e2509222122-1-e2509222122-12.
DOI Scopus8 WoS8 Europe PMC6
2025 Modi, N. D., Abuhelwa, A. Y., Kuderer, N. M., Li, L. X., Lyman, G. H., Koczwara, B., . . . Hopkins, A. M. (2025). Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. Cancer Medicine, 14(21), e71320-1-e71320-10.
DOI Scopus1 WoS1 Europe PMC2
2024 Neumann, D. P., Phillips, C. A., Lumb, R., Palethorpe, H. M., Ramani, Y., Hollier, B. G., . . . Gregory, P. A. (2024). Quaking isoforms cooperate to promote the mesenchymal phenotype. Molecular biology of the cell, 35(2), ar17-1-ar17-12.
DOI Scopus3 WoS2 Europe PMC3
2024 Neumann, D. P., Pillman, K. A., Dredge, B. K., Bert, A. G., Phillips, C. A., Lumb, R., . . . Gregory, P. A. (2024). The landscape of alternative polyadenylation during EMT and its regulation by the RNA-binding protein Quaking. RNA Biology, 21(1), 1-11.
DOI Scopus10 WoS9 Europe PMC39
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Research, 84(14), 2313-2332.
DOI Scopus50 WoS51 Europe PMC45
2024 Wang, Z., Townley, S. L., Zhang, S., Liu, M., Li, M., Labaf, M., . . . Cai, C. (2024). FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.. Nat Commun, 15(1), 4914.
DOI Scopus36 WoS40 Europe PMC52
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(6), 1092-1105.
DOI Scopus12 WoS13 Europe PMC15
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719.
DOI Scopus1 WoS2 Europe PMC2
2024 Rollin, S. P. G., Lawrence, M. G., Joshua, A. M., & Selth, L. A. (2024). Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer.. Endocrine-Related Cancer, 32(1), e240208-1-e240208-20.
DOI Scopus3 WoS4 Europe PMC2
2023 Scheinberg, T., Mak, B., Butler, L., Selth, L., & Horvath, L. G. (2023). Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology, 15, 1-30.
DOI Scopus38 WoS33 Europe PMC35
2023 John, A., Lim, A., Catterwell, R., Selth, L., & O’Callaghan, M. (2023). Length of positive surgical margins after radical prostatectomy: Does size matter? – A systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 26(4), 673-680.
DOI Scopus37 WoS37 Europe PMC31
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Gantley, L., Stringer, B. W., Conn, V. M., Ootsuka, Y., Holds, D., Slee, M., . . . Conn, S. J. (2023). Functional Characterisation of the Circular RNA, circHTT(2-6), in Huntington’s Disease. Cells, 12(9), 1-18.
DOI Scopus10 WoS9 Europe PMC12
2023 Conn, V. M., Gabryelska, M., Toubia, J., Kirk, K., Gantley, L., Powell, J. A., . . . Conn, S. J. (2023). Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia. Cancer Cell, 41(7), 1309-1326.e10.
DOI Scopus67 WoS63 Europe PMC65
2023 O'Callaghan, M. (2023). Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial. European Urology, 84(4), 440-441.
DOI
2023 Davies, A., Zoubeidi, A., Beltran, H., & Selth, L. A. (2023). The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity. Cancer Discovery, 13(8), OF1-OF18.
DOI Scopus117 WoS115 Europe PMC126
2023 Hinneh, J. A., Gillis, J. L., Mah, C. Y., Irani, S., Shrestha, R. K., Ryan, N. K., . . . Butler, L. M. (2023). Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. British Journal of Cancer, 129(8), 1350-1361.
DOI Scopus14 WoS15 Europe PMC15
2022 Guo, Z., Yang, C. T., Chien, C. C., Selth, L. A., Bagnaninchi, P. O., & Thierry, B. (2022). Optical Cellular Micromotion: A New Paradigm to Measure Tumor Cells Invasion within Gels Mimicking the 3D Tumor Environments. Small Methods, 6(8), 2200471-1-2200471-13.
DOI Scopus15 WoS15 Europe PMC11
2022 A, M., Owen, K. L., Townley, S., Zanker, D., Rollin, S. P. G., Hanson, A. R., . . . Selth, L. A. (2022). Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer research communications, 2(7), 706-724.
DOI Scopus18 WoS20 Europe PMC19
2022 Untitled Abstracts (2022). INTERNATIONAL JOURNAL OF UROLOGY, 29(S1), 5.
DOI
2022 Posters (2022). BJU International, 129(S2), 62-171.
DOI
2021 Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17.
DOI Scopus47 WoS48 Europe PMC50
2021 Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2021). The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nature Medicine, 27(2), 310-320.
DOI Scopus215 WoS205 Europe PMC205
2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993.
DOI Scopus70 WoS69 Europe PMC68
2021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
DOI Scopus80 WoS76 Europe PMC86
2021 Xie, J., De Poi, S. P., Humphrey, S. J., Hein, L. K., Bruning, J. B., Pan, W., . . . Proud, C. G. (2021). TSC-insensitive Rheb mutations induce oncogenic transformation through a combination of constitutively active mTORC1 signalling and proteome remodelling. Cellular and Molecular Life Sciences, 78(8), 4035-4052.
DOI Scopus6 WoS6 Europe PMC5
2021 John, A., John, H., Catterwell, R., Selth, L. A., & Callaghan, M. O. (2021). Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis. BJU International, 127(S1), 13-22.
DOI Scopus20 WoS22 Europe PMC18
2021 Choo, N., Ramm, S., Luu, J., Winter, J. M., Selth, L. A., Dwyer, A. R., . . . Simpson, K. J. (2021). High-throughput imaging assay for drug screening of 3D prostate cancer organoids. SLAS Discovery, 26(9), 1107-1124.
DOI Scopus66 WoS63 Europe PMC59
2021 Xie, J., Kusnadi, E. P., Furic, L., & Selth, L. A. (2021). Regulation of mRNA translation by hormone receptors in breast and prostate cancer. Cancers, 13(13), 3254-1-3254-26.
DOI Scopus17 WoS17 Europe PMC18
2021 Gillis, J. L., Hinneh, J. A., Ryan, N. K., Irani, S., Moldovan, M., Quek, L. -E., . . . Butler, L. M. (2021). A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife, 10, e62592-1-e62592-27.
DOI Scopus33 WoS35 Europe PMC39
2021 Davies, A., Nouruzi, S., Ganguli, D., Namekawa, T., Thaper, D., Linder, S., . . . Zoubeidi, A. (2021). An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.. Nature cell biology, 23(9), 33 pages.
DOI Scopus141 WoS136 Europe PMC159
2021 Che, M., Chaturvedi, A., Munro, S. A., Pitzen, S. P., Ling, A., Zhang, W., . . . Dehm, S. M. (2021). Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 12(1), 6377-1-6377-15.
DOI Scopus29 WoS30 Europe PMC38
2020 Davies, A. H., Zoubeidi, A., & Selth, L. A. (2020). The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. Endocrine-Related Cancer, 27(2), R35-R50.
DOI Scopus88 WoS89 Europe PMC89
2020 John, A., O'Callaghan, M., Catterwell, R., & Selth, L. (2020). Does Gleason score of positive surgical margin after radical prostatectomy affect biochemical recurrence and oncological outcomes? Protocol for systematic review. BMJ Open, 10(3), 4 pages.
DOI Scopus5 WoS5 Europe PMC3
2020 Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34.
DOI Scopus179 WoS172 Europe PMC179
2020 Montgomery, M. K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., . . . Watt, M. J. (2020). SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control. Science Translational Medicine, 12(559), 1-13.
DOI Scopus52 WoS51 Europe PMC46
2020 Tilley, W., Hickey, T., Selth, L., Chia, K. M., Milioli, H., Laven-Law, G., . . . Carroll, J. (2020). The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer.
DOI
2020 18th Urological Association of Asia (UAA) Congress, Leading Urology through Converging Asian Insight, 15-17 October 2020, Seoul, Korea (2020). International Journal of Urology Official Journal of the Japanese Urological Association, 27(S1), 5-165.
DOI Europe PMC1
2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). Abstract PO-036: ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress. Cancer Research, 80(23_Supplement).
DOI
2019 Warren, A., Massie, C., Watt, K., Luko, K., Orafidiya, F., Selth, L., . . . Asim, M. (2019). A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 38(7), 1136-1150.
DOI Scopus20 WoS19 Europe PMC17
2019 Das, R., Feng, F. Y., & Selth, L. A. (2019). Long non-coding RNAs in prostate cancer: biological and clinical implications. Molecular and Cellular Endocrinology, 480, 142-152.
DOI Scopus14 WoS12 Europe PMC11
2019 MacFawn, I., Wilson, H., Selth, L. A., Leighton, I., Serebriiskii, I., Bleackley, R. C., . . . Frisch, S. M. (2019). Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers. Molecular Immunology, 105, 137-149.
DOI Scopus26 WoS26 Europe PMC29
2019 Watt, M. J., Clark, A. K., Selth, L. A., Haynes, V. R., Lister, N., Rebello, R., . . . Taylor, R. A. (2019). Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Science Translational Medicine, 11(478), 1-12.
DOI Scopus296 WoS280 Europe PMC274
2019 Fernandes, R. C., Hickey, T. E., Tilley, W. D., & Selth, L. A. (2019). Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer. Endocrine-Related Cancer, 26(5), R237-R257.
DOI Scopus23 WoS23 Europe PMC22
2019 Holding, A. N., Giorgi, F. M., Donnelly, A., Cullen, A. E., Nagarajan, S., Selth, L. A., & Markowetz, F. (2019). VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer. Genome Biology, 20(1), 16 pages.
DOI Scopus26 WoS26 Europe PMC31
2019 Holding, A. N., Giorgi, F. M., Donnelly, A., Cullen, A. E., Nagarajan, S., Selth, L. A., & Markowetz, F. (2019). Correction to: VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer (Genome Biol (2019) 20:91 DOI: 10.1186/s13059-019-1698-z). Genome Biology, 20(1), 2 pages.
DOI WoS1
2019 Lorent, J., Kusnadi, E. P., van Hoef, V., Rebello, R. J., Leibovitch, M., Ristau, J., . . . Furic, L. (2019). Translational offsetting as a mode of estrogen receptor α-dependent regulation of gene expression. The EMBO Journal, 38(23), e101323-1-e101323-19.
DOI Scopus33 WoS32 Europe PMC43
2019 Nassar, Z., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M., . . . Butler, L. (2019). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
DOI
2018 Luo, J., Attard, G., Balk, S., Bevan, C., Burnstein, K., Cato, L., . . . Raj, G. (2018). Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 73(5), 715-723.
DOI Scopus116 WoS114 Europe PMC110
2018 Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14.
DOI Scopus34 WoS34 Europe PMC34
2018 Dhahbi, J. M., Atamna, H., & Selth, L. A. (2018). Data mining of small RNA-Seq suggests an association between prostate cancer and altered abundance of 5' transfer RNA halves in seminal fluid and prostatic tissues. Biomarkers in cancer, 10, 1-8.
DOI Europe PMC8
2018 Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19.
DOI Scopus25 WoS21 Europe PMC22
2018 Matin, F., Jeet, V., Moya, L., Selth, L., Chambers, S., Clements, J., & Batra, J. (2018). A plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer. Scientific Reports, 8(1), 6653-1-6653-15.
DOI Scopus84 WoS82 Europe PMC76
2018 Pillman, K. A., Phillips, C. A., Roslan, S., Toubia, J., Dredge, B. K., Bert, A. G., . . . Gregory, P. A. (2018). miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. EMBO Journal, 37(13), 20 pages.
DOI Scopus99 WoS99 Europe PMC99
2018 Lawrence, M., Obinata, D., Sandhu, S., Selth, L., Wong, S., Porter, L., . . . Frydenberg, M. (2018). Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy. European Urology, 74(5), 562-572.
DOI Scopus104 WoS101 Europe PMC96
2018 Holding, A., Giorgi, F., Donnelly, A., Cullen, A., Nagarajan, S., Selth, L., & Markowetz, F. (2018). Network analysis of ChIP-seq data by VULCAN identifies GRHL2 as a key co-regulator of ERa in luminal breast cancer.
DOI
2017 Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34.
DOI Scopus99 WoS98 Europe PMC91
2017 Leach, D. A., Panagopoulos, V., Nash, C., Bevan, C., Thomson, A. A., Selth, L. A., & Buchanan, G. (2017). Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome. Molecular and Cellular Endocrinology, 439(C), 261-272.
DOI Scopus24 WoS23 Europe PMC28
2017 Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034.
DOI Scopus105 WoS105 Europe PMC101
2017 Tse, B., Volpert, M., Ratther, E., Stylianou, N., Nouri, M., McGowan, K., . . . Hollier, B. (2017). Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 36(24), 3417-3427.
DOI Scopus68 WoS68 Europe PMC64
2017 Miao, L., Yang, L., Li, R., Rodrigues, D., Crespo, M., Hsieh, J., . . . Raj, G. (2017). Disrupting androgen receptor signaling induces Snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Research, 77(11), 3101-3112.
DOI Scopus79 WoS80 Europe PMC82
2017 Wang, Q., Selth, L., & Callen, D. (2017). MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4. Oncotarget, 8(18), 29914-29924.
DOI Scopus32 WoS34 Europe PMC26
2017 Paltoglou, S., Das, R., Townley, S., Hickey, T., Tarulli, G., Coutinho, I., . . . Selth, L. (2017). Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Research, 77(13), 3417-3430.
DOI Scopus88 WoS83 Europe PMC98
2017 Pedraza-Arévalo, S., Hormaechea-Agulla, D., Gómez-Gómez, E., Requena, M., Selth, L., Gahete, M., . . . Luque, R. (2017). Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. Prostate, 77(15), 1499-1511.
DOI Scopus36 WoS34 Europe PMC28
2017 Ponnusamy, S., Coss, C., Thiyagarajan, T., Watts, K., Hwang, D. -J., He, Y., . . . Narayanan, R. (2017). Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer. Cancer Research, 77(22), 6282-6298.
DOI Scopus82 WoS82 Europe PMC77
2016 Asim, M., Massie, C., Orafidiya, F., Pértega-Gomes, N., Warren, A., Esmaeili, M., . . . Neal, D. (2016). Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target. Journal of the National Cancer Institute, 108(5), djv371-1-djv371-13.
DOI Scopus51 WoS49 Europe PMC50
2016 Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13.
DOI Scopus12 WoS11 Europe PMC9
2016 Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page.
DOI Europe PMC1
2016 Hu, D., Selth, L., Tarulli, G., Meech, R., Wijayakumara, D., Chanawong, A., . . . Hickey, T. (2016). Androgen and estrogen receptors in breast cancer coregulate human UDP-glucuronosyltransferases 2B15 and 2B17. Cancer Research, 76(19), 5881-5893.
DOI Scopus55 WoS53 Europe PMC51
2016 Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559.
DOI Scopus23 WoS23 Europe PMC25
2016 Roberts, M. J., Richards, R., Chow, C. W. K., Schirra, H., Buck, M., Selth, L. A., . . . Gardiner, R. A. (2016). PROSTATIC FLUID MRNA AND MICRORNA BIOMARKERS: AN EMERGING PARADIGM FOR NONINVASIVE DIAGNOSIS OF PROSTATE CANCER. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 41.
2016 Coutinho, I., Day, T., Tilley, W., & Selth, L. (2016). Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocrine-Related Cancer, 23(12), T179-T197.
DOI Scopus172 WoS162 Europe PMC164
2015 Roberts, M., Chow, C., Schirra, H., Richards, R., Buck, M., Selth, L., . . . Gardiner, R. (2015). Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. The Prostate, 75(5), 539-549.
DOI Scopus39 WoS38 Europe PMC35
2015 Stegeman, S., Moya, L., Selth, L., Spurdle, A., Clements, J., & Batra, J. (2015). A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocrine-Related Cancer, 22(2), 265-276.
DOI Scopus53 WoS53 Europe PMC52
2015 Roberts, M. J., Richards, R. S., Gardiner, R. A., & Selth, L. A. (2015). Seminal fluid: a useful source of prostate cancer biomarkers?. Biomarkers in Medicine, 9(2), 77-80.
DOI Scopus18 WoS17 Europe PMC16
2015 Chan, S., Selth, L., Li, Y., Nyquist, M., Miao, L., Bradner, J., . . . Dehm, S. (2015). Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Research, 43(12), 5880-5897.
DOI Scopus136 WoS135 Europe PMC142
2015 Need, E., Selth, L., Trotta, A., Leach, D., Giorgio, L., O'Loughlin, M., . . . Buchanan, G. (2015). The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer, 15(1), 791-1-791-17.
DOI Scopus32 WoS28 Europe PMC27
2015 Hickey, T., Irvine, C., Dvinge, H., Tarulli, G., Hanson, A., Ryan, N., . . . Selth, L. (2015). Expression of androgen receptor splice variants in clinical breast cancers. Oncotarget, 6(42), 44728-44744.
DOI Scopus91 WoS82 Europe PMC82
2015 Raj, G. V., Selth, L. A., Day, T. K., & Tilley, W. D. (2015). Evolution of androgen deprivation therapy. Cancer Forum, 39(3), 189-194.
WoS1
2014 Hu, D., Hickey, T., Irvine, C., Wijayakumara, D., Lu, L., Tilley, W., . . . MacKenzie, P. (2014). Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues. Hormones and Cancer, 5(2), 61-71.
DOI Scopus61 WoS56 Europe PMC57
2014 Li, X., Roslan, S., Johnstone, C., Wright, J., Bracken, C., Anderson, M., . . . Khew-Goodall, Y. (2014). MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene, 33(31), 4077-4088.
DOI Scopus114 WoS108 Europe PMC110
2014 Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21.
DOI Scopus39 WoS35 Europe PMC36
2014 Das, R., Gregory, P., Hollier, B., Tilley, W., & Selth, L. (2014). Epithelial plasticity in prostate cancer: principles and clinical perspectives. Trends in Molecular Medicine, 20(11), 643-651.
DOI Scopus22 WoS22 Europe PMC21
2013 Sapre, N., & Selth, L. (2013). Circulating microRNAs as biomarkers of prostate cancer: the state of play. Prostate Cancer, 2013, 1-10.
DOI WoS40 Europe PMC44
2013 Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823.
DOI Scopus21 WoS19 Europe PMC20
2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650.
DOI Scopus118 WoS115 Europe PMC108
2013 Larsson, M., Uvell, H., Sandstrom, J., Ryden, P., Selth, L., & Bjorklund, S. (2013). Functional studies of the yeast Med5, Med15 and Med16 mediator tail subunits. PLoS One, 8(8), e73137-1-e73137-10.
DOI Scopus16 WoS15 Europe PMC16
2013 Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704.
DOI Scopus52 WoS51 Europe PMC47
2013 Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193.
DOI Scopus16 WoS14 Europe PMC14
2012 Need, E., Selth, L., Harris, T., Birrell, S., Tilley, W., & Buchanan, G. (2012). Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells. Molecular Endocrinology, 26(11), 1941-1952.
DOI Scopus78 WoS73 Europe PMC74
2012 Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68.
DOI Scopus19 WoS17 Europe PMC19
2012 Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613.
DOI Scopus48 WoS48 Europe PMC45
2012 Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113.
DOI Scopus39 WoS34 Europe PMC33
2012 Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672.
DOI Scopus35 WoS33 Europe PMC34
2012 Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661.
DOI Scopus166 WoS152 Europe PMC140
2011 Kumar, R., Selth, L., Schulz, R., Tay, B., Neilsen, P., & Callen, D. (2011). Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells. Journal of Cellular Biochemistry, 112(10), 2742-2747.
DOI Scopus20 WoS18 Europe PMC21
2011 Selth, L. A., Randles, J. W., & Ali Rezaian, M. (2011). Erratum: Agrobacterium tumefaciens supports DNA replication of diverse geminivirus types (FEBS Letters (2002) 516 (179-182)). FEBS Letters, 585(24), 4030.
DOI
2010 Selth, L., Sigurdsson, S., & Svejstrup, J. (2010). Transcript elongation by RNA polymerase II. Annual Review of Biochemistry, 79(1), 271-293.
DOI Scopus144 WoS143 Europe PMC145
2010 Kainov, D., Selth, L., Svejstrup, J., Egly, J., & Poterzsman, A. (2010). Interacting partners of the Tfb2 subunit from yeast TFIIH. DNA Repair, 9(1), 33-39.
DOI Scopus11 WoS11 Europe PMC10
2009 Selth, L., Lorch, Y., Ocampo-Hafalla, M., Mitter, R., Shales, M., Krogan, N., . . . Svejstrup, J. (2009). An Rtt109-independent role for Vps75 in transcription-associated nucleosome dynamics. Molecular and Cellular Biology, 29(15), 4220-4234.
DOI Scopus26 WoS25 Europe PMC27
2009 Selth, L., Gilbert, C., & Svejstrup, J. (2009). RNA immunoprecipitation to determine RNA-protein associations in vivo. Cold Spring Harbor Protocols, 4(6), 1-7.
DOI Scopus54 Europe PMC53
2009 Greenwood, C., Selth, L., Dirac-Svejstrup, A., & Svejstrup, J. (2009). An Iron-Sulfur Cluster Domain in Elp3 Important for the Structural Integrity of Elongator. Journal of Biological Chemistry, 284(1), 141-149.
DOI Scopus56 WoS45 Europe PMC48
2009 Eini Gandomani, O., Dogra, S., Selth, L., Dry, I., Randles, J., & Rezaian, M. (2009). Interaction with a Host Ubiquitin-Conjugating Enzyme Is Required for the Pathogenicity of a Geminiviral DNA beta Satellite. Molecular Plant-Microbe Interactions, 22(6), 737-746.
DOI Scopus85 WoS72 Europe PMC61
2007 Selth, L., & Svejstrup, J. (2007). Vps75, a new yeast member of the NAP histone chaperone family. Journal of Biological Chemistry, 282(17), 12358-12362.
DOI Scopus65 WoS64 Europe PMC68
2006 Selth, L., Dogra, S., Rasheed, M., Randles, J., & Rezaian, M. (2006). Identification and characterization of a host reversibly glycosylated peptide that interacts with the Tomato leaf curl virus V1 protein. Plant Molecular Biology, 61(1-2), 297-310.
DOI Scopus27 WoS23 Europe PMC19
2006 Rasheed, M., Selth, L., Koltunow, A., Randles, J., & Rezaian, M. (2006). Single-stranded DNA of Tomato leaf curl virus accumulates in the cytoplasm of phloem cells. Virology, 348(1), 120-132.
DOI Scopus26 WoS24 Europe PMC23
2005 Selth, L., Dogra, S., Rasheed, M., Healy, H., Randles, J., & Rezaian, M. (2005). A NAC domain protein interacts with tomato leaf curl virus replication accessory protein and enhances viral replication. Plant Cell, 17(1), 311-325.
DOI Scopus180 WoS149 Europe PMC120
2004 Selth, L., Randles, J., & Rezaian, M. (2004). Host responses to transient expression of individual genes encoded by Tomato leaf curl virus. Molecular Plant-Microbe Interactions, 17(1), 27-33.
DOI Scopus48 WoS40 Europe PMC37
2002 Selth, L., Randles, J., & Rezaian, M. (2002). Agrobacterium tumefaciens supports DNA replication of diverse geminivirus types. FEBS Letters, 516(1-3), 179-182.
DOI Scopus27 WoS29 Europe PMC27

Year Citation
2025 Lawrence, M., Keerthikumar, S., Townley, S., Clark, A., Cuffe, G., Laven-Law, G., . . . Selth, L. (2025). Androgen receptor genomic structural rearrangements reshape the AR cistrome in castration-resistant prostate cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 21 (pp. 119). WILEY.
2022 John, A., Catterwell, R., Lim, A., Selth, L., & O'Callaghan, M. (2022). Extension of positive surgical margins after radical prostatectomy: Does size matter? - A systematic review and meta-analysis. In BJU INTERNATIONAL Vol. 129 (pp. 139). Gold Coast, AUSTRALIA: WILEY.
2022 John, A., Milton, T., Gupta, A., Stretton, B., Hewitt, J., Catteerwell, R., . . . O'Callaghan, M. (2022). Location of positive surgical margins after radical prostatectomy- A systematic review and network meta-analysis. In BJU INTERNATIONAL Vol. 129 (pp. 26-27). Gold Coast, AUSTRALIA: WILEY.
2022 John, A., Milton, T., Gupta, A., Nguyen, M., Stretton, B., Hewitt, J., . . . O'Callaghan, M. (2022). Does location of positive surgical margins after radical prostatectomy matter?-A systematic review and network meta-analysis. In INTERNATIONAL JOURNAL OF UROLOGY Vol. 29 (pp. 13-14). WILEY.
2022 John, A., Lim, A., Catterwell, R., Seth, L., & O'Callaghan, M. (2022). Does size matter? Extension of positive surgical margins after radical prostatectomy - a systematic review and meta-analysis. In EUROPEAN UROLOGY Vol. 81 (pp. S258). ELSEVIER.
DOI
2020 John, A., John, H., Catterwell, R., Seth, L., & Callaghan, M. O. (2020). Gleason grade group of positive surgical margin predicts biochemical recurrence - a meta-analysis. In INTERNATIONAL JOURNAL OF UROLOGY Vol. 27 (pp. 57). WILEY.
2018 Selth, L. (2018). Toward Improved Treatment of Prostate Cancer: Novel Strategies to Target the Androgen Receptor. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 26-27). WILEY.
2018 Obinata, D., Lawrence, M., Taylor, R., Sandhu, S., Selth, L., & Risbridger, G. (2018). The efficacy of bromodomain inhibitor for multiple drug resistant CRPC using new patient-derived ex vivo models. In CANCER SCIENCE Vol. 109 (pp. 1024). WILEY.
2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2012 Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research.
DOI

Year Citation
2022 Tiruye, T., O' Callaghan, M., Moretti, K., Jay, A., Higgs, B., Santoro, K., . . . Beckmann, K. (2022). Patient-reported functional outcome measures at baseline and 12 months of commencing prostate cancer treatment. Poster session presented at the meeting of BJU International. UK: Wiley Blackwell Publishing.
DOI
2020 Lim, E., Hickey, T. A., Selth, L. A., Chia, K. M., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2020). The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. Poster session presented at the meeting of CANCER RESEARCH. TX, San Antonio: AMER ASSOC CANCER RESEARCH.
DOI
2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
WoS3
2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2019 Winter, J. M., Mustafa, E. H., Wang, S., Selth, L. A., Hickey, T. E., & Tilley, W. D. (2019). Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells <i>in vitro</i>. Poster session presented at the meeting of CANCER RESEARCH. GA, Atlanta: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2018 Matin, F., Jeet, V., Moya, L., Selth, L. A., Chambers, S., Clements, J. A., & Batra, J. (2018). A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer. Poster session presented at the meeting of Abstracts of the 19th Asia-Pacific Prostate Cancer Conference, as published in BJU International. Brisbane, AUSTRALIA: Wiley.
DOI
2018 Daniel, M. L., Hickey, T. E., Carroll, J. S., Tilley, W. D., Selth, L. A., & Dehm, S. M. (2018). Deciphering the regulome of androgen receptor variants in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI
2017 Selth, L. (2017). TOWARDS IMPROVED PROSTATE CANCER TREATMENT BY EXPLOITING MICRORNAS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2016 Asim, M., Massie, C., Warren, A., Luko, K., Chohan, B., Menon, S., . . . Neal, D. (2016). Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. New Orleans, LA: AMER ASSOC CANCER RESEARCH.
DOI
2015 Roberts, M. J., Chow, C. W. K., Schirra, H. J., Richards, R., Buck, M., Selth, L. A., . . . Gardiner, R. A. F. (2015). Diagnostic performance of PCA3, Hepsin and microRNA biomarkers in ejaculate in combination with serum PSA for the detection and triaging of prostate cancer. Poster session presented at the meeting of British Journal of Urology (BJU) International. Adelaide, Australia: Wiley.
DOI
2015 Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
2014 Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
2014 Hickey, T. E., Robinson, J. L., Moore, N. L., Russell, R., Selth, L., Rueda, O., . . . Tilley, W. D. (2014). The androgen receptor restricts estrogen receptor Alpha DNA binding in breast cancer cells. Poster session presented at the meeting of Endocrine Reviews. Chicago: Endocrine Society.
2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.

Year Citation
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Data from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2026). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S10 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S19 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S16 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 8 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S6 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 4 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Data from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S20 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 12 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S23 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S9 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 3 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S24 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S17 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 6 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S21 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S7 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S4 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 7 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S5 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S8 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S11 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 5 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S1 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S15 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 2 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 11 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S3 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 13 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S18 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S22 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S2 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 9 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 1 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S14 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S12 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Tab 10 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2026 Apostolov, E., Roden, D. L., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2026). Supp Fig S13 from Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy–Naïve Localized Prostate Cancer.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S10 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S12 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S11 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S13 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Dataset S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Data from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S3 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S8 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S5 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S9 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S6 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S7 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S1 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Table S2 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). Figure S4 from ACSM1 and ACSM3 Regulate Fatty Acid Metabolism to Support Prostate Cancer Growth and Constrain Ferroptosis.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI

Year Citation
2024 Apostolov, E., Roden, D., Holliday, H., Cazet, A., Harvey, K., Zhang, H., . . . Swarbrick, A. (2024). Profiling of epithelial functional states and fibroblast phenotypes in hormone therapy-naïve localised prostate cancer.
DOI
2022 Neumann, D., Pillman, K., Dredge, K., Bert, A., Bracken, C., Hollier, B., . . . Gregory, P. (2022). The landscape of alternative polyadenylation during EMT and its regulation by the RNA-binding protein Quaking.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2022 Co-Supervisor Alternative splicing networks and their impact on the development of aggressive prostate cancer Doctor of Philosophy Doctorate Full Time Miss Yesha Ramani
2021 Co-Supervisor Pathological parameters of positive surgical margins Doctor of Philosophy Doctorate Part Time Dr Athul Francis John

Date Role Research Topic Program Degree Type Student Load Student Name
2019 - 2023 Principal Supervisor Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer Doctor of Philosophy Doctorate Full Time Ms Meiwen Danielle Fang
2018 - 2023 Co-Supervisor Female Germline Formation During Plant Development Doctor of Philosophy Doctorate Full Time Mr Dayton Christopher Bird
2017 - 2021 Principal Supervisor Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Raj Kumar Shrestha
2017 - 2021 Principal Supervisor Extreme Activation of Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Mr Mohammadreza Alizadeh Ghodsi
2016 - 2020 Principal Supervisor The Role of MicroRNA-194 in Prostate Cancer Progression Doctor of Philosophy Doctorate Full Time Miss Rayzel Candida Fernandes
2014 - 2014 Principal Supervisor Curcumin Action in Prostate Cancer Cells and Fibroblasts Doctor of Philosophy Doctorate Full Time Miss Lauren Giorgio
2014 - 2017 Co-Supervisor MicroRNA Mediated Gene Regulation in Cancer Doctor of Philosophy Doctorate Full Time Ms Qingqing Wang
2013 - 2016 Co-Supervisor Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Heather Krista Armstrong
2013 - 2016 Principal Supervisor The Role of microRNA-194 and microRNA-375 in Prostate Cancer Metastasis Doctor of Philosophy Doctorate Full Time Dr Rajdeep Das
2011 - 2015 Co-Supervisor Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Miss Sarah Carter

Date Role Committee Institution Country
2016 - ongoing Member Adelaide Health and Medical School Research Reference Group - -
2015 - ongoing Member Faculty of Health Sciences Early/Mid Career Researcher Working Group University of Adelaide -
2014 - ongoing Member University of Adelaide Institutional Biosafety Committee University of Adelaide -

Date Role Editorial Board Name Institution Country
2017 - ongoing Board Member Endocrine-Related Cancer - -
2015 - ongoing Editor Scientific Reports (Nature Publishing Group) - -

Connect With Me

External Profiles

Other Links